FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approves Amgen's supplemental application for ARANESP (darbepoetin alfa), resulting in a label change for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Anemia
• Chronic Kidney Disease
• Hiv-associated Anemia

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

SUPPL AP for ARANESP (DARBEPOETIN ALFA)